Dividend updates
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty 100 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Reddy's Board recommended a final dividend of Rs. 8 per equity share (800% of face value Rs. 1) for FY25-26, subject to shareholder approval at the 42nd AGM on July 23, 2026. The record date for determining eligible shareholders is July 10, 2026. The company reported FY26 revenues of Rs. 335.9 billion (up 3.2% YoY) with profit after tax of Rs. 42.9 billion, though Q4FY26 saw significant decline due to lower Lenalidomide sales, one-time Shelf Stock Adjustment of Rs. 4,530 million, and impairments related to discontinued CAR-T programs. North America revenues fell 22% YoY to Rs. 113.7 billion due to lenalidomide impact.
The dividend of Rs. 8 per share represents a steady income return for shareholders. However, the weak Q4FY26 results with 90% YoY decline in profit before tax may create near-term stock price pressure despite the annual dividend declaration.